



Antimicrobial Prescribing and Stewardship, 2nd Volume

Guest Editor:

Dr. Diane Ashiru-Oredope

1. HCAI and AMR division, Public Health England, London, UK
2. Commonwealth Pharmacists Association, London E1W 1AW, UK

Deadline for manuscript submissions:

closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues,

The current COVID-19 pandemic is occurring amid the already ongoing global health crisis of antimicrobial resistance (AMR). Drug resistant infections/antimicrobial resistance are estimated to cause 700,000 deaths each year globally, and may complicate the care of COVID-19 patients, potentially leading to increased mortality and resulting in a significant economic burden.

Antimicrobial stewardship, as “a coherent set of actions which promote using antimicrobials in ways that ensure sustainable access to effective therapy for all who need them” (Dyar, O.J., 2017), is critical (alongside, e.g., infection prevention and control strategies) for tackling antimicrobial resistance/drug resistant infections.

“Volume 2 of the Special Edition of Antimicrobial Prescribing and Stewardship” Special Issue will consist of manuscripts, which may include original research, review articles, case series, and opinion papers. Relevant antimicrobial (antibiotic and antifungal) stewardship related topics will be considered for review.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)